Wegovy Dosing Schedule: Complete Step-by-Step Guide
The complete Wegovy (semaglutide 2.4mg) dosing schedule: from 0.25mg starter dose to maintenance, with clinical evidence on titration, side effects, and missed doses.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 8, 2026
Our medical review process ensures clinical accuracy and patient safety.
Introduction
Wegovy (semaglutide 2.4 mg) follows a carefully designed dose escalation schedule that plays a critical role in both its effectiveness and tolerability. Getting the titration right — not too fast, not skipping steps — is one of the most clinically important factors in treatment success.
The 5-step escalation protocol was established through the landmark STEP clinical trials program, where semaglutide achieved mean body weight reductions of 14.9%–17.4% at 68 weeks across multiple large randomized controlled trials.
Evidence: "The mean change in body weight from baseline to week 68 was −14.9% in the semaglutide group as compared with −2.4% with placebo, for an estimated treatment difference of −12.4 percentage points." — Wilding JPH, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
Understanding each phase of the Wegovy dosing schedule — what the dose is, why it exists, and what to expect — helps patients and clinicians maximize outcomes while minimizing unnecessary side effects.
The Wegovy Dosing Schedule: Phase by Phase
Wegovy uses a 16-week dose escalation before reaching the target maintenance dose of 2.4 mg once weekly. Each escalation step lasts exactly 4 weeks.
Full Dose Escalation Table
| Phase | Weeks | Dose (subcutaneous, once weekly) | Purpose |
|---|---|---|---|
| Initiation | 1–4 | 0.25 mg | Gastrointestinal adaptation |
| Escalation 1 | 5–8 | 0.5 mg | Gradual receptor titration |
| Escalation 2 | 9–12 | 1.0 mg | Increasing weight loss effect |
| Escalation 3 | 13–16 | 1.7 mg | Approaching maintenance |
| Maintenance | 17 onward | 2.4 mg | Long-term weight management |
Step 1: 0.25 mg (Weeks 1–4)
The starting dose of 0.25 mg is not a therapeutic dose — it produces little to no weight loss on its own. Its sole purpose is to let the gastrointestinal tract adapt to GLP-1 receptor activation. Starting here significantly reduces the frequency and severity of nausea, vomiting, and diarrhea.
Clinical note: Do not attempt to stay at 0.25 mg longer than 4 weeks hoping to "ease in" more gently. The titration schedule is clinically validated; prolonging sub-therapeutic doses delays benefit without additional GI protection.
Step 2: 0.5 mg (Weeks 5–8)
At 0.5 mg, patients begin to notice appetite suppression and early weight loss. Nausea may appear in this phase but is typically mild and transient. Eating smaller meals, avoiding high-fat foods, and injecting at night can help manage early GI effects.
Step 3: 1.0 mg (Weeks 9–12)
The 1.0 mg dose corresponds to the therapeutic dose used in Ozempic (for type 2 diabetes). Weight loss becomes clinically meaningful in this phase. Patients who tolerate 1.0 mg well typically have smooth escalation to higher doses.
Step 4: 1.7 mg (Weeks 13–16)
The penultimate step before maintenance. Weight loss continues to accelerate. GI side effects, if they recurred at 1.0 mg, often stabilize by week 12–14 as adaptation continues.
Step 5: 2.4 mg (Week 17 onward — Maintenance)
The 2.4 mg maintenance dose is where Wegovy's full efficacy is achieved. This is a Wegovy-specific dose — the only FDA-approved formulation delivering this level of semaglutide for weight management in adults without type 2 diabetes.
Evidence: "Across STEP 1, 3, 4 and 8, semaglutide 2.4 mg was associated with mean weight losses of 14.9%–17.4% in individuals with overweight or obesity without type 2 diabetes from baseline to week 68; 69%–79% of participants achieved ≥10% weight loss." — Singh G, et al. Drugs Context. 2022. PMC9272494
Why Gradual Escalation Matters
The GLP-1 receptor system controls gastric emptying, satiety signaling, and gut motility. Activating these receptors too rapidly overwhelms the system, causing severe nausea and vomiting — the primary reasons patients discontinue early.
The pooled analysis of STEP 1, 2, and 3 trials found that most gastrointestinal adverse events occurred during or shortly after dose escalation, not at the maintenance phase. Crucially, 98.1% were classified as mild-to-moderate in severity, and only 4.3% of participants permanently discontinued due to GI events.
Evidence: "Most gastrointestinal adverse events with semaglutide were non-serious (99.5%), mild-to-moderate (98.1%), transient, and occurred most frequently during or shortly after dose escalation." — Davies M, et al. Diabetes Obes Metab. 2022. DOI: 10.1111/dom.14551
GI Side Effect Frequency by Symptom
| Side Effect | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Nausea | 43.9% | 16.1% |
| Diarrhea | 29.7% | 15.9% |
| Vomiting | 24.5% | 6.3% |
| Constipation | 24.2% | 11.1% |
Source: STEP 1–3 pooled analysis (Davies et al., 2022)
What to Do If You Can't Tolerate a Dose
Tolerance problems are common and expected. The FDA-approved prescribing information explicitly supports dose escalation delays as a clinical strategy.
Approved Delay Protocol
If a patient cannot tolerate moving to the next escalation step:
- Extend the current dose by an additional 4 weeks before attempting the increase
- If the next escalation is still not tolerated, delay again for another 4 weeks
- If 2.4 mg maintenance is not tolerated, the prior tolerated dose (e.g., 1.7 mg) may serve as an individualized maintenance dose
Practical Management Tips
- Inject at bedtime — nausea peaks 8–12 hours after injection; sleeping through this window reduces perceived severity
- Reduce meal size — Wegovy slows gastric emptying; large meals cause discomfort at any dose
- Avoid high-fat, high-spice meals on injection day and the day after
- Stay hydrated — especially important if experiencing diarrhea or vomiting
- Never inject more frequently than once weekly — increasing frequency does not improve weight loss and significantly worsens tolerability
Long-Term Efficacy: What the 2-Year Data Shows
The STEP 5 trial followed patients on semaglutide 2.4 mg for 104 weeks (2 years), providing the longest published efficacy data for Wegovy.
Evidence: "The mean change in body weight from baseline to week 104 was −15.2% in the semaglutide group versus −2.6% with placebo, for an estimated treatment difference of −12.6 percentage points (P < 0.0001)." — Garvey WT, et al. Nat Med. 2022. DOI: 10.1038/s41591-022-02026-4
Key finding: weight loss was sustained at 2 years, without evidence of significant plateau beyond what was achieved at week 68. This is a clinically meaningful result, as many weight loss interventions show regression after 12–18 months.
Missed Dose Protocol
Real-world adherence to weekly injections is imperfect. The FDA-approved guidance for missed doses:
| Time Since Missed Dose | Action |
|---|---|
| ≤ 5 days late | Inject as soon as possible; resume weekly schedule |
| > 5 days late | Skip missed dose; inject on the next regularly scheduled day |
Never double-dose. If you miss a dose and your next scheduled injection is within 5 days, wait for the regular schedule rather than taking two doses close together.
Wegovy vs. Ozempic: Same Drug, Different Doses
A point of common confusion: both Wegovy and Ozempic contain semaglutide, but they are not interchangeable for weight management.
| Wegovy | Ozempic | |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Max dose | 2.4 mg/week | 2.0 mg/week |
| FDA indication | Chronic weight management | Type 2 diabetes |
| Target population | BMI ≥30 (or ≥27 with comorbidity) | Adults with T2D |
| Pen design | Single-dose pens | Multi-dose pen |
The 2.4 mg dose in Wegovy is 20% higher than the maximum Ozempic dose and was specifically evaluated in the STEP program for its weight management efficacy. Learn more about the differences in our Ozempic vs. Wegovy comparison.
Who Should Consider Slower Titration
While the standard 4-week-per-step schedule works for most patients, clinical evidence and real-world data support extended titration for certain populations:
- History of GERD or gastroparesis — GLP-1 medications slow gastric emptying and can worsen these conditions; slower titration allows better assessment
- Prior GI surgery — altered anatomy may increase sensitivity to GI effects
- Older adults (>65) — often have lower baseline GI motility; slower escalation reduces constipation risk
- Concurrent medications — patients on metformin or other GI-affecting drugs may benefit from extended steps
A real-world analysis from an academic obesity clinic confirmed that individualized titration (slower than the clinical trial protocol) was common in practice and associated with better persistence without compromising long-term weight loss outcomes.
Evidence: "Real-world titration practices for semaglutide frequently deviate from clinical trial protocols, with slower escalation in patients with GI sensitivity, without significant impact on weight loss outcomes at 12 months." — PMC12515774. PMC
Key Takeaways
- Wegovy follows a 5-step, 16-week escalation from 0.25 mg to the 2.4 mg maintenance dose
- Each step lasts 4 weeks minimum — never advance faster than this interval
- Gastrointestinal side effects are expected, peak during escalation, and are mild-to-moderate in 98% of cases
- If a dose is not tolerated, delay escalation by 4 weeks — do not discontinue prematurely
- At 2 years, mean weight loss of 15.2% is maintained with continued treatment
- Missed doses ≤5 days late: inject immediately; >5 days: skip and resume on schedule
For patients newly starting Wegovy, the first 16 weeks are the adjustment period — most of the medication's long-term benefit comes from maintaining the 2.4 mg maintenance dose consistently. Patience through the escalation phase is directly linked to treatment success.
References
Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. DOI: 10.1038/s41591-022-02026-4
Davies M, Færch L, Jeppesen OK, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. Diabetes Obes Metab. 2022;24(10):1869-1879. DOI: 10.1111/dom.14551
Singh G, Kumar A, Arora S. Once-Weekly Semaglutide for Weight Management: A Clinical Review. Drugs Context. 2022;11:2022-5-2. PMC: PMC9272494
Garvey WT, Mechanick JI, Brett EM, et al. Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations. Drug Des Devel Ther. 2022;17:3007-3017. PMC: PMC9807016
U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. 2023. FDA
Last updated: 2026-03-08 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.